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OBJECTIVES We surveyed the literature to estimate prediction values for five common tests for risk of
major arrhythmic events (MAEs) after myocardial infarction. We then determined feasibility
of a staged risk stratification using combinations of noninvasive tests, reserving an electro-
physiologic study (EPS) as the final test.
BACKGROUND Improved approaches are needed for identifying those patients at highest risk for subsequent
MAE and candidates for implantable cardioverter-defibrillators.
METHODS We located 44 reports for which values of MAE incidence and predictive accuracy could be
inferred: signal-averaged electrocardiography; heart rate variability; severe ventricular arrhyth-
mia on ambulatory electrocardiography; left ventricular ejection fraction; and EPS. A
meta-analysis of reports used receiver-operating characteristic curves to estimate mean values
for sensitivity and specificity for each test and 95% confidence limits. We then simulated a
clinical situation in which risk was estimated by combining tests in three stages.
RESULTS Test sensitivities ranged from 42.8% to 62.4%; specificities from 77.4% to 85.8%. A
three-stage stratification yielded a low-risk group (80.0% with a two-year MAE risk of 2.9%),
a high-risk group (11.8% with a 41.4% risk) and an unstratified group (8.2% with an 8.9% risk
equivalent to a two-year incidence of 7.9%).
CONCLUSIONS Sensitivities and specificities for the five tests were relatively similar. No one test was
satisfactory alone for predicting risk. Combinations of tests in stages allowed us to stratify
91.8% of patients as either high-risk or low-risk. These data suggest that a large prospective
study to develop a robust prediction model is feasible and desirable. (J Am Coll Cardiol 2001;
38:1902–11) © 2001 by the American College of Cardiology
Sudden cardiac death (SCD) is a major public health
problem in both the U.S. and worldwide (1). In the U.S.,
coronary heart disease accounts for about 85% of episodes of
SCD (2). Although some studies have suggested that
certain drugs may reduce SCD (3–5), other trials with
antiarrhythmic medications have shown a higher mortality
on drug therapy (6,7). In contrast, several recent studies
have demonstrated clearly that implantable cardioverter-
defibrillators (ICDs) reduce SCD mortality significantly
(8–12).
See page 1912
Consensus guidelines (13) regarding indications for ICD
implantation, however, cover only a minority of patients
who die of SCD. Thus, there have been recent calls for
better ways to identify those patients without an ICD who
are at highest risk for SCD, because they are the ones most
likely to benefit from prophylactic insertion of an ICD
(14–16).
In this report we evaluate the utility of tests currently used
for risk stratification of patients who have had a myocardial
infarction (MI); most studies evaluating such tests have
been done in post-MI patients. We used a reported tech-
nique for combining independent studies of a given diag-
nostic test into a summary receiver-operating characteristic
(ROC) curve; this produced estimates for overall predictive
accuracy (17). We then evaluated the effectiveness of com-
bining noninvasive tests, and we also evaluated obtaining
noninvasive tests in a staged manner, with an electrophysi-
ologic study (EPS) as the final test. Our aim was to simulate
a possible clinical approach. We also considered the mon-
etary costs of this approach. The data for our study came
from 44 reports in the literature (18–61).
METHODS
Report retrieval. Relevant reports were found by searching
Medline using the following keywords: myocardial infarct,
sudden cardiac death, risk stratification, ventricular fibrilla-
tion (VF), ventricular tachycardia (VT), signal-averaged
electrocardiogram (SAECG), heart rate variability (HRV),
left ventricular function, ejection fraction, ambulatory elec-
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trocardiography (AECG) and EPS. Additional reports were
located with the aid of review articles. Only reports in
English were used. About 80% of selected studies have been
published since 1990. Reports were selected only if they
contained adequate quantitative data to characterize patients
and events as detailed in the following text. The follow-up
period in most reports was at least one year. If several
reports from the same institution appeared to describe the
same prognostic tests on the same patients, then only one
report from that institution was used.
Tests were selected for study of their prognostic value if
at least 9 to 10 articles were found that each had 100 or
more patients (one study selected had only 86 patients) and
if the data could be analyzed using the approaches described
below. Noninvasive tests selected were SAECG, left ven-
tricular ejection fraction (LVEF) (as determined by echo-
cardiography or nuclear scintigraphy) and AECG, which
provides two tests, namely the presence of serious ventric-
ular arrhythmia (SVA) and a measure of HRV. Invasive
tests selected were programmed stimulation on EPS and
LVEF from left ventriculography.
We use the term “major arrhythmic events” (MAEs) to
describe the various episodes of fatal or life-threatening
arrhythmic events reported in the surveyed papers. These
events included episodes of SCD, resuscitated SCD, and
defibrillation or cardioversion of VF or VT. Most reports
used the criteria of the Cardiac Arrhythmia Suppression
Trial (6) to define a MAE.
Data extraction. For each report, the numbers of true-
positive, true-negative, false-positive and false-negative re-
sults were recorded as integer values. In most reports, these
numbers were not explicitly given. When they were not
given, we used the stated values for the number of patients
studied, the sensitivity, specificity and predictive accuracy,
and we estimated the integer values using standard formu-
las. If necessary, the estimated integer values were adjusted
to produce, to three decimal places, those values for sensi-
tivity, specificity and predictive accuracy that most closely
approximated (usually within 0.5%) the values for the latter
stated in the report.
Data analysis. For each risk stratification test, totals for all
the reports were collected (Table 1). The one-year and
two-year MAE rates for each report were modeled by using
its value for MAE-free survival and its value for mean or
median follow-up time, by assuming that MAE-free sur-
vival decreases exponentially with time. The aggregate
one-year and two-year MAE rates for a collection of reports
are average values weighted by the number of patients in
each report.
We then constructed a summary ROC curve for each
individual test, using the technique of Moses et al. (17).
Weighted composite mean values for sensitivity and speci-
ficity and 95% confidence intervals (CI) for each were
located on the summary ROC curve (Fig. 1, Table 2). The
composite values of sensitivity and specificity were com-
bined with the total MAE rate to derive estimates for
predictive accuracy and risk (Table 2). The MAE risk after
a positive test is equal to the positive predictive accuracy
(PPA) of that test, and MAE risk after a negative test is
equal to 100 minus the negative predictive accuracy (NPA).
To determine whether use of revascularization therapy for
MI influenced event rates, we compared the data in reports
published through 1993 with those published after 1993.
The annualized incidence (weighted average) for the 22
reports published in 1993 and before was 3.8%, and for the
22 reports published after 1993 was 4.4%; hence, a trend in
this survey for higher annualized incidences after 1993 was
not significant (p  0.51). The annualized incidence for 12
reports on SAECG published in 1993 and before was 4.6%,
and for 10 SAECG reports published after 1993 was 4.1%;
this trend for lower annualized incidences for SAECG
reports after 1993 was not significant (p  0.81).
Using the composite values for sensitivity and specificity
in Table 2, the percentages of patients with various expected
risks for several different test combinations were estimated
and are shown in Table 3.
Cost estimates for the various tests were obtained from an
American College of Cardiology Expert Consensus docu-
ment (62).
RESULTS
Performances of individual tests. The results of combin-
ing studies are shown in Figure 1 and Tables 1 and 2.
The incidences of MAE in the patient populations
reported (references 18–61; column 2 in Table 1) are the
prior probabilities for MAE—that is, the probability of a
MAE prior to a test. The individual values of prior
probability varied widely (range 3.3% to 34.1%). As noted
below, we obtained a weighted overall two-year prior
probability of 7.9% for the 44 reports in this study.
The risk of MAE after a test is the posterior probability,
Abbreviations and Acronyms
AECG  ambulatory electrocardiography
CI  confidence interval
EPS  electrophysiologic study
HRV  heart rate variability
ICD  implantable cardioverter-defibrillator
LVEF  left ventricular ejection fraction
MADIT  Multicenter Automatic Defibrillator
Implantation Trial
MAE  major arrhythmic event
MI  myocardial infarction
NPA  negative predictive accuracy
PPA  positive predictive accuracy
ROC  receiver-operating characteristic
SAECG  signal-averaged electrocardiogram
SCD  sudden cardiac death
SVA  serious ventricular arrhythmia
VF  ventricular fibrillation
VT  ventricular tachycardia
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Table 1. Bayesian Statistics for Five Tests Used to Predict Risk of MAEs After Myocardial Infarction
References
Prior Probability
(Incidence of
MAE) (%)
No. of
Patients
Average
Follow-Up
(months) TP FN TN FP Sensitivity Specificity
Positive
Predictive
Accuracy
Relative
Risk
Odds
Ratio
A. SAECG STUDIES
Ahuja (18) 6.5 262 10.5 6 11 234 11 0.353 0.955 0.353 7.9 11.6
Breithardt (19) 11.8 628 39.0 40 34 345 209 0.541 0.623 0.161 1.8 1.9
De Chillou (20) 7.4 244 57.0 11 7 155 71 0.611 0.686 0.134 3.1 3.4
Denniss (21) 7.5 306 36.0 15 8 218 65 0.652 0.770 0.188 5.3 6.3
el-Sherif (22) 3.9 1,158 12.0 22 23 1,002 111 0.489 0.900 0.165 7.4 8.6
Farrell (23) 5.8 416 36.5 15 9 318 74 0.625 0.811 0.169 6.1 7.2
Gomes (24) 13.9 115 14.0 12 4 60 39 0.750 0.606 0.235 3.8 4.6
Hermosillo (25) 8.7 196 12.0 16 1 129 50 0.941 0.721 0.242 31.5 41.3
Kozer (26) 7.3 261 12.0 14 5 206 36 0.737 0.851 0.280 11.8 16.0
Kuchar (27) 9.0 233 31.0 17 4 137 75 0.810 0.646 0.185 6.5 7.8
Lander (28) 9.2 173 14.0 11 5 129 28 0.688 0.822 0.282 7.6 10.1
Ma¨kija¨rvi (29) 4.3 776 6.0 25 8 467 276 0.758 0.629 0.083 4.9 5.3
McClements (30) 3.7 297 12.4 7 4 232 54 0.636 0.811 0.115 6.8 7.5
Ohnishi (31) 8.0 100 18.0 6 2 67 25 0.750 0.728 0.194 6.7 8.0
Pedretti (32) 6.3 303 15.0 12 7 219 65 0.632 0.771 0.156 5.0 5.8
Richards (33) 6.2 225 12.0 8 6 173 38 0.571 0.820 0.174 5.2 6.1
Savard (34) 3.3 2,461 17.0 52 28 1,672 709 0.650 0.702 0.068 4.1 4.4
Sierra (35) 5.5 769 23.0 18 24 618 109 0.429 0.850 0.142 3.8 4.3
Steinberg (36) 8.8 182 14.0 11 5 103 63 0.688 0.620 0.149 3.2 3.6
Strasberg (37) 12.0 100 12.0 7 5 65 23 0.583 0.739 0.233 3.3 4.0
Verzoni (38) 2.7 220 12.0 5 1 157 57 0.833 0.734 0.081 12.7 13.8
Zimmermann (39) 7.0 458 70.0 15 17 351 75 0.469 0.824 0.167 3.6 4.1
SAECG Total 9,883
B. STUDIES OF SVA ON AECG
Bigger (40) 14.1 715 30.0 48 53 461 153 0.475 0.751 0.239 2.3 2.7
el-Sherif (22) 3.9 1,158 12.0 27 18 791 322 0.600 0.711 0.077 3.5 3.7
Farrell (23) 5.8 416 36.5 13 11 319 73 0.542 0.814 0.151 4.5 5.2
Gomes (24) 14.5 110 14.0 13 3 54 40 0.813 0.574 0.245 4.7 5.9
Hermosillo (25) 10.5 200 12.0 8 13 165 14 0.381 0.922 0.364 5.0 7.3
Hohnloser (41) 7.7 325 30.0 4 21 255 45 0.160 0.850 0.082 1.1 1.1
Kostis (42) 4.6 1,640 25.0 12 64 1,464 100 0.158 0.936 0.107 2.6 2.7
Kuchar (27) 7.3 206 31.0 11 4 129 62 0.733 0.675 0.151 5.0 5.7
La Rovere (43) 3.8 1,170 21.0 14 30 946 180 0.318 0.840 0.072 2.3 2.5
McClements (30) 4.3 301 12.4 5 8 214 74 0.385 0.743 0.063 1.8 1.8
Mukharji (44) 5.4 533 18.0 10 19 438 66 0.345 0.869 0.132 3.2 3.5
Pedretti (32) 6.3 303 15.0 13 6 190 94 0.684 0.669 0.121 4.0 4.4
Richards (33) 4.5 358 12.0 13 3 137 205 0.813 0.401 0.060 2.8 2.9
Ruberman (45) 7.3 1,739 60.0 69 58 1,225 387 0.543 0.760 0.151 3.3 3.8
Steinberg (36) 8.8 182 14.0 7 9 121 45 0.438 0.729 0.135 1.9 2.1
Verzoni (38) 2.9 208 12.0 4 2 144 58 0.667 0.713 0.065 4.7 5.0
SVA Total 9,564
C. STUDIES OF HRV ON AECG
Bigger (46) 14.1 715 30.0 42 59 579 35 0.416 0.943 0.545 5.9 11.8
Copie (47) 4.7 551 24.0 12 14 462 63 0.462 0.880 0.160 5.4 6.3
Farrell (23) 5.8 416 36.5 22 2 301 91 0.917 0.768 0.195 29.5 36.4
Hohnloser (41) 7.7 325 30.0 15 10 246 54 0.600 0.820 0.217 5.6 6.8
Katz (48) 34.1 185 16.0 30 33 87 35 0.476 0.713 0.462 1.7 2.3
Kleiger (49) 15.7 808 31.0 43 84 599 82 0.339 0.880 0.344 2.8 3.7
La Rovere (43) 3.8 1,170 21.0 17 27 969 157 0.386 0.861 0.098 3.6 3.9
Lanza (50) 7.9 239 28.0 6 13 202 18 0.316 0.918 0.250 4.1 5.2
Malik (51) 10.6 451 21.9 24 24 293 110 0.500 0.727 0.179 2.4 2.7
Pedretti (32) 6.1 292 15.0 16 2 187 87 0.889 0.682 0.155 14.7 17.2
Zuanetti (52) 9.2 567 32.9 22 30 446 69 0.423 0.866 0.242 3.8 4.7
HRV Total 5,719
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that is, the risk of MAE given knowledge of the test result.
In Table 2 we provide the sensitivities, specificities and
posterior probabilities for the five individual tests of interest.
Sensitivities ranged from 43% to 62%, but with considerable
overlapping of 95% CI.
Specificities were higher, ranging from 77% to 86%, again
with much overlapping of 95% CI. The two-year PPA, the
risk of a MAE given a positive test result, was highest for
HRV and EPS, and lowest for SVA (Table 2). The
two-year risk of a MAE with a negative test (negative
predictive accuracy, or NPA) was lowest for EPS and
SAECG, and highest for HRV.
Performance of risk stratification tests can also be com-
pared by estimating relative risk (i.e., the ratio of the PPA
and [1  NPA]). Relative risk was highest for EPS (6.6)
and lowest for SVA (2.9). Another way to compare tests is the
odds ratio, which was also highest for EPS (8.5) and lowest for
SVA (3.2). Note that relative risk depends on the incidence of
MAE in the population, but that the odds ratio does not.
Risk implications of combined tests. In all the reports of
Table 1, there were 25,543 patients, with a weighted overall
estimated two-year MAE incidence of 7.9%. Many reports
contributed results for more than one test. In order to
construct Table 3, an estimated two-year MAE incidence of
7.9% was used as a prior probability. Furthermore, to
explore implications of combining tests the analysis was
simplified by using only the composite weighted mean
values for sensitivity and specificity.
Table 3 represents a staged application of noninvasive tests
followed by the use of EPS. With this approach, the first step
would be performance of both SAECG and LVEF at a cost of
$275 per patient (62). If the two tests were both negative or
both positive (as would be true for 64.2% of the patients, Table
3), further testing would not be done, as the two-year proba-
bility of a MAE would be very low in the former situation
(2.2%), and high enough in the latter situation (38.7%) to
warrant consideration of ICD implantation.
The second step would be performance of a 24-h
Table 1. (Continued)
References
Prior Probability
(Incidence of
MAE) (%)
No. of
Patients
Average
Follow-Up
(months) TP FN TN FP Sensitivity Specificity
Positive
Predictive
Accuracy
Relative
Risk
Odds
Ratio
D. LVEF STUDIES
Bigger (40) 14.1 715 30.0 59 42 446 168 0.584 0.726 0.260 3.0 3.7
De Chillou (20) 7.4 244 57.0 10 8 188 38 0.556 0.832 0.208 5.1 6.2
Copie (47) 8.1 520 24.0 17 25 373 105 0.405 0.780 0.139 2.2 2.4
el-Sherif (22) 3.9 1,158 12.0 32 13 768 345 0.711 0.690 0.085 5.1 5.5
Farrell (23) 5.8 416 36.5 11 13 294 98 0.458 0.750 0.101 2.4 2.5
Gomes (24) 14.5 110 14.0 11 5 69 25 0.688 0.734 0.306 4.5 6.1
Hermosillo (25) 11.9 201 12.0 17 7 142 35 0.708 0.802 0.327 7.0 9.9
Hohnloser (41) 7.7 325 30.0 12 13 261 39 0.480 0.870 0.235 5.0 6.2
Iesaka (53) 8.3 133 24.0 6 5 106 16 0.545 0.869 0.273 6.1 8.0
Kuchar (27) 7.1 210 31.0 13 2 144 51 0.867 0.738 0.203 14.8 18.4
Lander (28) 9.2 173 14.0 9 7 121 36 0.563 0.771 0.200 3.7 4.3
La Rovere (43) 3.8 1,276 21.0 22 27 1,045 182 0.449 0.852 0.108 4.3 4.7
McClements (30) 4.0 300 12.4 9 3 233 55 0.750 0.809 0.141 11.1 12.7
Pedretti (32) 6.3 303 15.0 15 4 242 42 0.789 0.852 0.263 16.2 21.6
Richards (33) 4.9 347 12.0 12 5 243 87 0.706 0.736 0.121 6.0 6.7
Rodriguez (54) 17.4 190 25.0 15 18 124 33 0.455 0.790 0.313 2.5 3.1
Steinberg (36) 8.8 182 14.0 9 7 101 65 0.563 0.608 0.122 1.9 2.0
Strasberg (37) 12.0 100 12.0 5 7 69 19 0.417 0.784 0.208 2.3 2.6
Verzoni (38) 5.4 111 12.0 4 2 65 40 0.667 0.619 0.091 3.0 3.3
Zabel (55) 6.8 280 32.0 11 8 185 76 0.579 0.709 0.126 3.1 3.3
LVEF Total 7,294
E. EPS
Bhandari (56) 12.8 86 18.0 6 5 62 13 0.545 0.827 0.316 4.2 5.7
Brembilla-Perrot (57) 8.5 492 44.4 29 13 262 188 0.690 0.582 0.134 2.8 3.1
Bourke (58) 4.0 1,000 28.0 12 28 912 48 0.300 0.950 0.200 6.7 8.1
Denniss (21) 6.7 403 36.0 14 13 309 67 0.519 0.822 0.173 4.3 5.0
Iesaka (53) 8.3 133 24.0 9 2 106 16 0.818 0.869 0.360 19.4 29.8
Middlekauff (59) 6.9 523 12.0 22 14 403 84 0.611 0.828 0.208 6.2 7.5
Richards (33) 3.8 313 12.0 7 5 286 15 0.583 0.950 0.318 18.5 26.7
Viskin (60) 14.9 786 25.5 105 12 241 428 0.897 0.360 0.197 4.2 4.9
Zoni-Berisso (61) 3.8 286 12.0 6 5 272 3 0.545 0.989 0.667 36.9 108.8
EPS Total 4,022
AECG  ambulatory electrocardiography; EPS  electrophysiologic study; FN  false negative; FP  false positive; HRV  heart rate variability; LVEF  left ventricular
ejection fraction; MAE  major arrhythmic event; SAECG  signal-averaged electrocardiography; SVA  serious ventricular arrhythmia; TN  true negative; TP  true
positive.
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Figure 1. Receiver-operating characteristic (ROC) curves for the five tests evaluated in the study. The curves were generated using the approach of Moses et al. (17). AECG ambulatory electrocardiography;
ECG  electrocardiogram.
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AECG (an additional $165 per patient) in the 35.8%
of patients who had only a positive SAECG or only a
low LVEF, resulting in an intermediate risk for a
MAE (10.6% over two years). If SVA and HRV were
both normal or both abnormal (25%), no further testing
would be needed, because in the former situation, the
posterior probability is still below the original prior
probability, despite having either an abnormal SAECG
or a low LVEF, and in the latter case, the posterior
probability would again be high enough to warrant
consideration of ICD implantation.
The third step would involve the remaining 10.8% of the
original patients, who would have an intermediate risk of
17.5% (Table 3). They would undergo an EPS (at an
additional $1,220 cost). Thus, 2.6% of the original group
would have a positive EPS, again with a two-year risk high
enough (45.1%) to justify consideration of ICD implanta-
tion.
The aggregate results show that at the end of applying all
three stages, there is a small proportion (8.2%) of unstrati-
fied patients with essentially the same risk (8.9%) as the
original prior probability (7.9%).
DISCUSSION
Sensitivity and specificity are inherent characteristics of a
given test, and they do not depend on the incidence of the
disease or condition in the population being studied, and
they also do not depend on the probability of the disease or
condition in the individual. However, the values obtained
for sensitivity and specificity do depend on the spectrum of
patients or subjects included in the evaluation. For example,
Table 2. Comparison of Tests for Predicting MAEs
Test
(No. of
Reports)
Number of
Patient
Studies
Prior Probability
(i.e., Total MAE
Incidence)
(Annualized)
Composite Weighted
Values for
Two-Year Probability
of a MAE if Relative
Risk
(Test/
Test)
Odds
Ratio
[(TP/FP)/
(FN/TN)]
Sensitivity
(95% CI)
Specificity
(95% CI)
Test ()
(95% CI)
Test ()
(95% CI)
ECG-Based Tests
SAECG (22) 9,883 7.99% (4.1%) 62.4% 77.4% 19.3% 4.05% 4.8 5.7
(56.4%–67.9%) (73.6%–80.8%) (18.3%–20.3%) (3.65%–4.48%)
SVA (16) 9,564 6.50% (3.33%) 42.8% 80.9% 13.4% 4.68% 2.9 3.2
(32.7%–53.7%) (75.0%–85.7%) (13.0%–13.7) (4.12%–5.18%)
HRV (11) 5,719 9.02% (4.72%) 49.8% 85.8% 25.8% 5.48% 4.7 6.3
(37.5%–62.1%) (82.1%–88.9%) (25.0%–25.6%) (4.37%–6.52%)
Left Ventricular Function
LVEF (20) 7,294 8.57% (4.41%) 59.1% 77.8% 20.0% 4.70% 4.3 5.1
(53.3%–64.6%) (75.5%–79.9%) (19.8%–19.9%) (4.21%–5.19%)
Electrophysiologic Studies
EPS (9) 4,022 8.11% (4.17%) 61.6% 84.1% 25.5% 3.88% 6.6 8.5
(48.2%–73.4%) (65.0%–93.8%) (15.6%–40.7%) (3.49%–4.65%)
CI  confidence interval; other abbreviations as in Table 1.
Table 3. Staged Application of Tests for Prediction of a MAE*
Test Combinations Results of Tests
Proportion of
Population (%)
Probability
(Predictive Accuracy)
of a MAE Over
2 Years (%)
Stage 1  SAECG and LVEF Both negative 56.6 2.2
Only 1 positive 35.8 10.6
Both positive 7.6 38.7
Stage 2  AECG (SVA and HRV)
performed on “only 1 positive”
patient of stage 1
Both negative 23.3 4.7
Only 1 positive 10.8 17.5
Both positive 1.7 48.2
Stage 3  EPS performed on
“only 1 positive” patient in stage 2
Negative 8.2 8.9
Positive 2.6 45.1
Aggregate results Low-risk group 80.0 2.9
High-risk group 11.8 41.4
Unstratified group 8.2 8.9
Low LVEF, SVA and positive EPS
(MADIT criteria)
1.9 66.5
*Probability of MAE based on composite means of sensitivities and specificities (prior probability)  7.9%.
MADIT  Multicenter Automatic Defibrillator Implantation Trial; other abbreviations as in Table 1.
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if LVEF is used to evaluate the risk of a MAE by comparing
LVEFs in a group of healthy young subjects with a group of
post-MI patients with very low LVEFs, sensitivity and
specificity will appear to be much higher than when the risk
is evaluated in only a group of post-MI patients with a wide
range of LVEFs. This is likely one of the reasons that the
separate sensitivities and specificities for a given test re-
ported in Table 1 vary so widely. Other causes for the
variances would include different cutoff points used in
different studies, different measurement techniques, and
experimental error.
Positive predictive accuracy of a test does depend on the
incidence of the disease or condition in the population
studied, and it also depends on the time since performance
of the test. Thus, the differences in the prior probabilities in
Table 1 also contribute to the differences in PPA, in
addition to the factors causing variances in sensitivity and
specificity mentioned in the previous text.
The significance of results in individual reports is com-
promised by a relatively low number of MAEs in each
report surveyed. By estimating a global MAE rate (global
MAE count/global patient count) over all the reports for
each method, and by constructing summary ROC curves,
we are better able to appreciate the different performances of
risk stratification tests. By using thousands of patients, as
opposed to hundreds in the individual reports, we achieve
better accuracy and precision for the estimates of sensitivity
and specificity for the different tests. Also, by using larger
numbers of patients, plausible values for expected outcomes
from combining tests could be reasonably simulated.
Using standard Bayesian formulas, it can be shown that
risks increase with higher prior probabilities. Therefore,
relative risk depends in part upon the global MAE incidence
(or prior probability), whereas the odds ratio as well as
sensitivity and specificity can be regarded as independent of
MAE incidence.
Sources of variation in reports. Population variation from
one risk stratification test to the next was evident in the
different report values for prior probabilities (Table 1).
There was also some diversity in the analytic approach used
for the reported tests, especially in HRV. For example, some
studies reported HRV as a standard deviation or an index
(time domain), whereas others reported values for power
derived from fast Fourier transforms (frequency domain).
However, each report of a given test reflects the same aspect
of the basic pathophysiology.
We assumed in the meta-analysis that the investigators in
each report attempted to optimize criteria—that is, to
choose cutoff points that gave the best separation of patients
with MAE from those without MAE. Of course, the choice
of a cutoff point affects the (always present) trade-off
between sensitivity and specificity. If that trade-off were the
only source of variation, the data for the individual reports
would closely fit the summarizing ROC curve. That they do
not probably also reflects study population variations be-
tween different reports more than differing analytic tests.
For purposes of the survey collection and comparison in
Table 1, report results were taken at face value, with no
attempt to adjust them to make criteria uniform from report
to report.
Choosing a threshold that arbitrarily segments the data is
a fundamental problem with all reports surveyed. For
example, a patient with an LVEF of 0.39 and another with
an LVEF of 0.41 should clearly have similar risks, but by
choosing a threshold of 0.40 they are arbitrarily separated
into different risk categories.
Reinhardt et al. (63) proposed a solution to this problem.
Their model accounted for the time of event occurrence
after hospital discharge for each patient (25 MAE events in
a population of 553 post-MI patients). Such a model could
project a single risk versus time function for each patient,
taking into account that risk decreases as time after MI
increases. The transition of predicted probability of events
between high and low groups would be continuous for test
parameters and would not be stepwise with fixed cutoff
thresholds.
Another source of variation resulted from the lack of a
distinction between cardiac death and SCD in some reports,
but where the focus was upon some measure of electrophysi-
ologic or autonomic disturbance. In addition, VT/VF may
not necessarily be the proximate cause of sudden death;
bradyarrhythmias, acute reinfarction, pulmonary embolism,
stroke and aneurismal rupture have also been implicated in
SCD (64).
Effect of correlation on test combinations. The patho-
physiology of infarct is related to the size and location of the
lesion and should be directly manifested in the various
parameters for electrical instability (SAECG, ventricular
premature beats, EPS) and in mechanical integrity (LVEF);
its effect upon the autonomic system (HRV) may be
somewhat less direct. Hence, some degree of correlation
between the parameters of electrical instability can be
expected and possibly a lesser degree between those param-
eters and LVEF or HRV.
When two tests, A and B, are combined (A  B), there
are true positives for A, but not B, (A  B)  B; true
positives for B, but not A, (A  B)  A; and true positives
for both A and B, (A  B). The effect of correlation would
be to increase the true positives for both, (A  B), at the
expense of the other positives, (A  B)  (A  B). Also,
because there would be a higher proportion of both tests
positive relative to the false positives, the estimate for risk
would be increased. Similarly, with both tests correlated and
negative, a higher proportion of patients would have a lower
risk. The effect upon results in Table 3 could be to improve
greatly the risk stratification in the first two stages and to
reduce the proportion of patients referred for EPS from
10.8% to 3.2%.
Unfortunately, quantitative estimates for degree of corre-
lation between tests are not available from the literature, and
this problem has not been well studied. Therefore, in
constructing Table 3 the worst case was to assume no
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correlation (i.e., independence) of tests. That assumption
produces the most conservative estimate of what happens
when two tests are combined.
Cost-effective combinations of tests. Some investigators
have proposed a staged approach to determine risk for
post-MI patients (32,65,66). With the staged approach
shown in Table 3, the projected cost would be about $415
per patient averaged out over the post-MI population.
Implications for therapy. One must beware of cursorily
applying group statistics to an individual patient. The
clinical course of the individual patient must be carefully
assessed in addition to the noninvasive tests. Nevertheless,
based on a study of post-MI patients with inducible VT or
VF that responded to drugs, Andresen et al. (67) found an
almost 30% occurrence rate of SCD or sustained VT during
a 14- to 24-month follow-up; as this incidence is as high as
the recurrence rate for patients who had been resuscitated
from VF—a group now routinely treated with ICD—they
suggest that any asymptomatic post-MI patient with a risk
near 30% should be considered for a prophylactic ICD.
Conclusions. Table 3 shows that it may be feasible to
stratify as many as 90% of post-MI patients into “high risk”
(30%) and “low risk” (3%) categories using combina-
tions of four noninvasive risk stratification tests and reserv-
ing the invasive, expensive EPS for patients where the
noninvasive tests are inconclusive.
Many would accept that the 2% of post-MI patients
who meet the stringent criteria of the recent ICD trials
(8–12) should receive an ICD, and two recent studies
purport to demonstrate the cost-effectiveness of doing so
(68,69). Indeed, using the positive criteria for acceptance
into the Multicenter Automatic Defibrillator Implantation
Trial (MADIT) (9,68), our simulation results project a
two-year risk for MAE of over 66%, which is very similar to
the 60% incidence of a first ICD discharge within two years
in the MADIT study itself (9). Only 1.9% of the 25,000
post-MI patients in our study meet the MADIT criteria,
however (see bottom line of Table 3). This projection of
1.9% is comparable to the findings of Every et al. (70), who
estimated that no more than 1.1% of post-MI patients meet
the MADIT criteria. However, our study suggests that
there may be another 10% of post-MI patients who do not
meet such stringent criteria but who do probably meet a
criterion of a 30% risk. If, as Andresen et al. suggest (67),
these patients should be treated prophylactically with ICDs,
a very large expenditure in a sizable population is implied, in
which perhaps 50% to 70% of the patients may not benefit
from an ICD; the cost-effectiveness of ICDs in such
patients may be difficult to demonstrate.
The further resolution of these issues may require another
study such as that of Reinhardt et al. (63), in a much larger
population, with the goal of constructing a robust risk
model with continuous parameters that would allow better
individualized risk predictions for each patient.
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